Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides’ management and Board also participated in the round.